Navigation Links
Positive Results from Phase 2 Trial of Mesoblast's Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting
Date:11/14/2011

ORLANDO, Florida and MELBOURNE, Australia, November 14, 2011 /PRNewswire/ --

 

  • Revascor™, Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) product for cardiovascular diseases, was safe and well-tolerated at all doses, with no clinically relevant immune responses to donor cells
  • Revascor™ therapy significantly reduced cardiac mortality and major adverse cardiac events (MACE) in patients with congestive heart failure over a mean follow-up of 22 months
  • Highest dose of Revascor™ completely prevented any episodes of heart failure hospitalization over 18 months of follow-up
  • Clinical improvement was associated with evidence of remodeling (reduction in heart volumes) and improvement in functional capacity (increased walking distance), which are key parameters in congestive heart failure
  • Revascor™ anticipated to progress to Phase 3 trial in first half of 2012

Regenerative medicine company Mesoblast Limited (ASX:MSB; OTC ADR:MBLTY) today announced positive Phase 2 heart failure trial results of its allogeneic, or off-the-shelf, adult stem cell product Revascor™ after all patients had completed a minimum follow-up of 12 months, and a mean follow-up of 22 months. The Phase 2 trial results were presented at the American Heart Association annual meeting in Orlando, Florida, by the trial's independent principal investigator Dr Emerson C. Perin, Director of Research in Cardiovascular Medicine and Medical Director, Stem Cell Center, Texas Heart Institute in Houston.

MPC treatment pooled across all doses resulted in significant reduction in cardiac mortality, and at the highest dose resulted in complete preven
'/>"/>

SOURCE Mesoblast
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Positive Data for Nektars New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
2. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
3. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
4. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
5. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
6. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
7. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
9. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
10. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
11. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Inc. (Vanda) (NASDAQ: VNDA ) today announced that ... of the Year by the Tech Council of ... 25 th Annual Tech Awards Celebration held in ... the leaders and innovators in the technology and life science ... regions. "We are deeply honored to receive ...
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. ... stage medical device company that develops and sells high ... of its rights offering.  In addition, the concurrent temporary ... warrants expired on May 17, 2013. Nephros ... million from the rights offering.   A portion of the ...
(Date:5/23/2013)... May 23, 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, ... companies, based on intellectual property developed and owned ... ,s foremost medical research center, today announced that ... significant funding from the Israeli Ministry of Industry ... to support product development and advance clinical trials. ...
Breaking Medicine Technology:Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... EDISON, N.J., July 15, 2011 Crestor ... designed to lower "bad cholesterol". Both drugs are classified ... inhibiting HMG-CoA reductase. This group of drugs has had ... to Crestor and Zocor, touted as a "super statin" ...
... N.J., July 15, 2011 Janssen Pharmaceuticals, Inc. ... assets of its Ortho Dermatologics division in the ... for approximately $345 million in cash. The divestiture ... MICRO®, ERTACZO® and RENOVA®) sold in the U.S. ...
Cached Medicine Technology:Crestor and Zocor Drugs Linked to Muscle Degeneration, Rhabdomyolysis 2Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division 2
(Date:5/25/2013)... 2013 Dr. Farooq Ashraf, founder of ... Dubai, has announced his practice’s adoption of The iFS ... FDA-cleared femtosecond laser proven with more than 10 years ... of LASIK. , “We are happy to announce that ... at our Dubai LASIK practice,” Ashraf said Thursday. “We ...
(Date:5/25/2013)... Acuity Games ’ innovative brain games have ... Word Hunt is available today, expanding it beyond its ... 2, Sudoku and Matchematics will roll out over the next ... lifetime brain fitness measurement have been re-optimized for the iPhone's ... brain fitness measurement in your pocket. What could be ...
(Date:5/25/2013)... Los Angeles, CA (PRWEB) May 25, 2013 ... will grow at an average annual rate of 28.7% ... growth of 17.9% in 2013. From 2002 and 2008, no ... analyst Kevin Culbert, causing relatively modest growth during that period. ... (FDA) has approved six new products. This factor contributed to ...
(Date:5/25/2013)... May 25, 2013 For college ... finals week. Increasingly, they are turning to prescription ... and study. For more on this, go to ... treatment facility, warns that students who pick up ... at risk for developing a physical and psychological ...
(Date:5/25/2013)... Ayurveda is the traditional medicine of ... of life". While a medical science, its scope enters into ... Its fundamental philosophy is that disease is the end result ... that in order to re-establish optimal health, we must discover ... a life style which brings us back into harmony. , ...
Breaking Medicine News(10 mins):Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Acuity Games Apps Come to the iPhone 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes 2
... test, based on gene expression and predicting the tumours that ... was presented today at the 3rd International Conference on innovative ... Dr Robert Takes, from the Radboud University Nijmegen Medical Centre, ... of oral or oropharyngeal cancer. The study was jointly led ...
... of the factors reported by those who say they are unhappy ... its kind, published in the launch issue of the new online ... challenge the perception that these patients can no longer enjoy quality ... the authors. The research team quizzed 168 members of the ...
... 24 (HealthDay News) -- An analysis of proteins in spinal ... with chronic fatigue syndrome, a new study reports. It ... involve the central nervous system and that protein abnormalities in ... conditions, said the research team, which was led by Dr. ...
... microbiological equilibrium in the female genital tract can lead ... Deutsches rzteblatt International ( Dtsch Arztebl Int ... Bitzer investigates a method of screening for such changes., ... preterm deliveries. To avoid these, in a model project ...
... . , When the family doctor is a woman, patients ... their health problem, especially when it is a family health problem ... family doctor "listening to them, keeping them informed and considering their ... conclusion drawn of a study recently conducted by Ana Delgado, ...
... Feb. 24 (HealthDay News) -- Most "locked-in syndrome" patients -- ... be happy, according to a new study. People with ... except through eye movements or blinking. Patients with the condition ... surveyed 91 locked-in syndrome patients in France about their medical ...
Cached Medicine News:Health News:Gene expression to distinguish metastasizing from non-metastasizing head and neck cancers 2Health News:Most 'locked-in syndrome' patients say they are happy 2Health News:Spinal Fluid May Hold Clues to Lyme Disease, Chronic Fatigue Syndrome 2Health News:When the doctor is a woman, patients expect them to be involved in decision making 2Health News:Most 'Locked-In Syndrome' Patients Happy, Survey Finds 2
This is long known for its purity and mildness, Castile Soap is also an effective cleaning agent that is used in a variety of applications. It rinses clean while leaving the skin soft and healthy....
Upon application to intact skin, Skin-Prep* protective wipes forms a protective film that prepares the skin for the attachment of drainage tubes, external catheters, adhesive dressings and can be...
Triad Plus Sterile Isopropyl Alcohol 70% USP Prep Pads are medium size. Each package is terminally sterilized, ensuring the safest possible product....
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
Medicine Products: